Crossmark

Regulatory considerations for successful implementation of digital endpoints in clinical trials for drug development

Published Online: 2025-03-06

Authors

Erdemli, Gül https://orcid.org/0000-0003-4677-2914
Murphy, Tina

Walinsky, Sarah
License Information

Text and Data Mining valid from 2025-03-06

Version of Record valid from 2025-03-06
More Information

Article History

Received: 25 July 2024

Accepted: 11 February 2025

First Online: 6 March 2025

Competing interests

: G.E., T.M. and S.W. are employees of Novartis and may hold shares in the company but have no non-financial competing interests.

Document is current